PLK

PLK Targeted Therapies Market & Clinical Trials 2024: Onvansertib Leading the Way in PLK1 Inhibition, Pioneering Breakthroughs in Small Cell Lung Cancer and Chronic Myelomonocytic Leukemia Treatment - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 7, 2024
Health, Clinical Trials, Cytokinesis, Immunotherapy, Cancer, Chronic myelomonocytic leukemia, Inflammation, Disorder, Safety, Breast cancer, Viral, Apoptosis, SCLC, Cell proliferation, Research, Cell cycle, Carcinoma, DNA, Mitosis, Indication, Patient, Rheumatoid arthritis, Hepatitis B virus, Virus, Proteolysis targeting chimera, Multiple sclerosis, HIV, Messenger, PLK, Lupus, Genome, Biomarker, Medicine, PLK1, DA, HBV, Pharmaceutical industry

The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials.
  • The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
  • In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas.

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Retrieved on: 
Monday, March 11, 2024
APRE, Toxicity, Cyclin E, FDA, Cancer, Food, PLK, Breast, Safety, Therapy, Clinical trial, IND, WEE1, Pharmaceutical industry

DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application (IND 169359) for APR-1051.

Key Points: 
  • “APR-1051 is a next-generation inhibitor of WEE1 kinase and, based on its unique characteristics, we believe it will be best in class,” said Dr. Oren Gilad, President and CEO of Aprea.
  • “The FDA's clearance of our IND is a critical step in the APR-1051 development program.
  • Aprea has conducted extensive pre-clinical studies with APR-1051, which have demonstrated that the molecule has potent anti-tumor activity, along with a favorable pharmacokinetic (PK) profile.
  • *
    Clearance of the IND application will allow Aprea to initiate the Phase 1 ACESOT-1051 dose escalation trial to evaluate the safety, tolerability, and preliminary efficacy of APR-1051.

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Breast cancer, PLK4, Cancer, Prevalence, TRIM37, Abstract, Neoplasm, Patient, PLK

ORIC-613 is highly selective against the kinome, including against the closely related aurora kinases and other PLK family members.

Key Points: 
  • ORIC-613 is highly selective against the kinome, including against the closely related aurora kinases and other PLK family members.
  • Preclinical assessment in cancer cell lines revealed the synthetic lethality, with ORIC-613 having stronger potency in TRIM37-high cells as evidenced by inducing tumor cell death specifically in TRIM37-high versus TRIM37-wildtype cells.
  • Analysis of genomic data from adult tumors indicates that increased TRIM37 copy number is found across a breadth of cancers, with notable prevalence in breast cancer.
  • Oral dosing of ORIC-613 resulted in tumor growth inhibition and regressions in TRIM37-high xenograft breast tumors.

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Retrieved on: 
Tuesday, February 6, 2024
APRE, Investigational New Drug, DNA, Patient, IND, Safety, FDA, PLK, Therapy, Non-Euclidean geometry, WEE1, Pharmaceutical industry

APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA damage repair.

Key Points: 
  • APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA damage repair.
  • * Aprea has conducted extensive pre-clinical studies with APR-1051, which have demonstrated that the molecule may have highly potent anti-tumor activity, with a potentially favorable pharmacokinetic (PK) profile.
  • “Submission of an IND represents an important milestone for our APR-1051 development program,” said Dr. Oren Gilad, President and CEO of Aprea.
  • “APR-1051 is a next generation inhibitor of WEE1 kinase and, based on its unique characteristics, we believe it will be best in class.

Restaurant Brands International Inc. Announces Revised Segment Reporting

Retrieved on: 
Monday, January 8, 2024
Depreciation, AOI, FHS, QSP, Popeyes, PLK, Restaurant Brands, Kobza, QSR, Bank statement, Adjustment, BK, Burger King, Growth, Investment, RBI, TSX, Firehouse Subs

The TH, BK, PLK and FHS segments include results from each brands' operations in the United States and Canada.

Key Points: 
  • The TH, BK, PLK and FHS segments include results from each brands' operations in the United States and Canada.
  • INTL includes consolidated results from each brands' operations outside of the United States and Canada.
  • In addition, RBI has transitioned its definition of segment income from Adjusted EBITDA to Adjusted Operating Income ("AOI").
  • We have four amazing brands being led by five ambitious leaders across our home markets and international.

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Retrieved on: 
Thursday, January 4, 2024
ATR, Aplastic anemia, IND, DDR, Principal, FDA, Spacecraft, Breast, WEE1, Data, APRE, PLK1, PLK, PLK2, Complex conjugate, HERG, Therapy, Pharmacokinetics, PLK3, Cancer, PARP, Prostate, Toxicity, Patient, Safety, Non-Euclidean geometry, ADC, NSCLC, History, Pharmaceutical industry

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.

Key Points: 
  • DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.
  • The most recent analysis of the data cut (January 2, 2024) shows that two patients have achieved stable disease – one each in the 50 mg and 200 mg cohorts.
  • Upon the addition of the higher dose cohorts, Aprea expects to determine the recommended Phase 2 dose (RP2D) in the second half of 2024.
  • Aprea will be hosting institutional investor and business development meetings at the Annual Corporate Access Event in San Francisco, hosted by our investor relations firm LifeSci Partners.

Connected Home IT Startup, Led by Mukthtar Quanyshbayuly, to Expand Business to Gulf Region and USA

Retrieved on: 
Thursday, November 16, 2023
Movement, Software, PLK, Temperature, Smoke, Zawar Farid, Safety

Abu Dhabi, United Arab Emirates--(Newsfile Corp. - November 16, 2023) - Connected Home is looking to expand its business to the Middle East region.

Key Points: 
  • Abu Dhabi, United Arab Emirates--(Newsfile Corp. - November 16, 2023) - Connected Home is looking to expand its business to the Middle East region.
  • Connected Home, a pioneering IT startup in Kazakhstan, doesn't just stop at controlling smart devices; it crafts entire ecosystems.
  • Connected Home isn't just a convenience; it's a lifestyle, redefining the very essence of modern living.
  • The company is also looking to expand to the US after successful business cases in the MENA region.

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 9, 2023
HERG, Synthetic lethality, DDR, Acquisition, Safety, MD Anderson Cancer Center, WEE1, Therapy, University, PLK3, Gynecologic oncology, IND, ATR, PLK, Patient, PLK1, Division, FDA, Conference, Cardiotoxicity, Cell death, Ovarian cancer, APRE, Anemia, Poster, KOL, PLK2, AACR, Pharmaceutical industry, Aprea-Cuccaro clan

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.
  • “We are very pleased by the progress of our diversified programs this past quarter.
  • “We are continuing with patients in the dose escalation portion of the study, and the dose expansion cohort is on track to be initiated in 2Q 2024.
  • The first poster included initial data from the Company’s first-in-human Phase 1/2a dose escalation trial of ATRN-119 in solid tumors.

Restaurant Brands International Inc. Announces New Segment Reporting and Key Dates for 2024

Retrieved on: 
Thursday, December 14, 2023
NYSE, RBI, Burger King, Bank statement, FHS, QSP, PLK, Restaurant Brands, BK, Calendar, Popeyes, TSX, Firehouse Subs, QSR, Food delivery

In addition, RBI announced key 2024 dates, including an upcoming Investor Event on February 15, 2024, and preliminary 2024 earnings call dates.

Key Points: 
  • In addition, RBI announced key 2024 dates, including an upcoming Investor Event on February 15, 2024, and preliminary 2024 earnings call dates.
  • The TH, BK, PLK and FHS segments include results from each brands' operations in the United States and Canada.
  • RBI will continue to provide key operational metrics by brand for their respective home markets and consolidated international markets.
  • The company will be available to discuss any questions related to the shift in segment reporting following the release through January 19, 2024.

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Retrieved on: 
Monday, October 16, 2023
WEE1, Cell cycle, AACR, IND, Therapy, SD, PLK, APRE, PLK1, ATR, Poster, HERG, PLK2, PLK3, Conference, Patient, Toxicity, Pharmaceutical industry

ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors to determine the recommended Phase 2 dose, with a daily dosing administration over a 56-day cycle.

Key Points: 
  • ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors to determine the recommended Phase 2 dose, with a daily dosing administration over a 56-day cycle.
  • This preclinical compound exhibits high potency for WEE1 inhibition in vitro and shows low off-target inhibition of the PLK family.
  • The preclinical data findings and sensitivity to our WEE1 asset is guiding our clinical strategy and future patient selection.
  • We look forward to advancing the drug to IND in the fourth quarter of this year.”